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We  performed  antimicrobial  drug  susceptibility  test-
ing  and  molecular  typing  on  invasive  methicillin-resistant 
Staphylococcus aureus (MRSA) isolates (n = 1,666) sub-
mitted to the University of Iowa Hygienic Laboratory during 
1999–2006 as part of a statewide surveillance system. All 
USA300 and USA400 isolates were resistant to <3 non–β-
lactam antimicrobial drug classes. The proportion of MRSA 
isolates from invasive infections that were either USA300 
or USA400 increased significantly from 1999–2005 through 
2006 (p<0.0001). During 2006, the incidence of invasive 
community-associated (CA)–MRSA infections was highest 
in the summer (p = 0.0004). Age <69 years was associated 
with an increased risk for invasive CA-MRSA infection (odds 
ratio [OR] 5.1, 95% confidence interval [CI] 2.06–12.64), 
and hospital exposure was associated with decreased risk 
(OR 0.07, 95% CI 0.01–0.51).
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ethicillin-resistant Staphylococcus  aureus  (MRSA) 
emerged in the 1960s and has since become a ma-
jor  cause  of  illness  and  death  in  the  healthcare  setting 
(1,2). Risk factors for infection with healthcare-associated 
MRSA (HA-MRSA) include hospitalization, residence in 
a long-term care facility, older age, invasive devices (e.g., 
catheters,  feeding  tubes),  and  exposure  to  antimicrobial 
agents. HA-MRSA isolates are often resistant to several 
antimicrobial drug classes in addition to β-lactams (3).
In the 1990s, investigators began describing serious 
MRSA infections among persons who did not have typical 
risk factors for infections with this organism (2,4–8). These 
community-associated MRSA (CA-MRSA) infections af-
fected young, healthy persons (4,5,7) and were associated 
with factors such as participating in contact sports, shar-
ing towels or athletic equipment, using illegal intravenous 
drugs, and living in crowded or unsanitary areas (e.g., pris-
ons, hurricane evacuee centers) (9,10).
Pulsed-field gel electrophoresis (PFGE) demonstrated 
that  MRSA  strains  causing  these  community-associated 
infections  (USA300  and  USA400)  were  different  than 
those  causing  healthcare-associated  infections  (USA100 
and USA200) (11). USA300 and USA400 MRSA strains 
typically  have  the  staphylococcal  cassette  chromosome 
(SCC) mec type IV, not the SCCmec type II carried by 
most  USA100  and  USA200  isolates  (12).  In  addition, 
USA300/400 isolates usually carry the gene that encodes 
the  Panton-Valentine  leukocidin  (PVL),  a  bicomponent 
(lukF-PV and lukS-PV) pore-forming leukotoxin (8,13–15). 
Currently, the role of PVL in the pathogenesis of infections 
caused  by  USA300/400  isolates  is  controversial.  Epide-
miologic studies and a study by Labandeira-Rey et al. sug-
gest that PVL is associated with virulence and causes the 
necrosis characteristic of infections with these strains (16). 
In contrast, a study by Voyich et al. found no difference 
in virulence between the wild-type parent strains and the 
isogenic knockout strains that did not produce PVL (17).
A recent multicenter study by Moran et al. showed 
that USA300 MRSA is now the most common cause of 
skin and soft tissue infections (SSTIs) among adults seek-
ing treatment in emergency departments in 11 large met-
ropolitan areas (15). USA300 also causes serious invasive 
infections  such  as  necrotizing  pneumonia,  bloodstream 
infections, and surgical site infections, some of which are 
acquired in hospitals (18–22). Although most USA300 and 
USA400 isolates are currently resistant to fewer classes of 
antimicrobial drugs than are HA-MRSA isolates (13), a re-
cent paper by Han et al. identified a USA300 subtype that is 
resistant to erythromycin, clindamycin (constitutive), tetra-
cycline, mupirocin, and fluoroquinolones (23).
Most epidemiologic studies of CA-MRSA have ex-
amined isolates from SSTIs infections (7,15,18), and most 
studies that evaluated patients with invasive disease have 
involved single healthcare facilities (21,24) or isolates ob-
tained primarily from large urban areas (22). We describe 
the molecular epidemiology of invasive infections caused 
by USA300 and USA400 in a rural state. We characterized 
invasive MRSA from 1999–2005 (select isolates) and in 
2006 (all isolates) submitted to the statewide surveillance 
system in Iowa for invasive MRSA infections.
Methods
As part of a statewide surveillance system, the Iowa 
Department of Public Health has mandated since 1999 that 
clinical microbiology laboratories submit invasive isolates 
of MRSA to the University Hygienic Laboratory (UHL), 
Iowa’s public health laboratory (25,26). After performing 
antimicrobial drug susceptibility testing on all isolates, we 
further characterized (by PFGE, PVL detection, and SCC-
mec typing) all isolates from 1999–2005 that were resistant 
to ≤3 non–β-lactam antimicrobial drug classes (i.e., consis-
tent with USA300/400) and all 343 isolates from unique 
patients with invasive infections submitted to the UHL dur-
ing 2006.
Antimicrobial Drug Susceptibility Testing
All invasive MRSA isolates during 1999–2006 were 
tested  for  antimicrobial  drug  susceptibility  by  the  broth 
dilution method described by the Clinical and Laboratory 
Standards Institute (27). Invasive isolates were defined as 
any organism from a normally sterile body site such as 
blood, cerebrospinal fluid, pleural fluid, joint fluid, or fluid 
from a liver abscess. Isolates from urine were excluded.
Isolates were tested for susceptibility to tetracycline, 
erythromycin,  clindamycin,  trimethoprim/sulfamethox-
azole,  gentamicin,  levofloxacin,  moxifloxacin,  linezolid, 
daptomycin,  vancomycin,  and  rifampin.  Multidrug-re-
sistant isolates were defined as MRSA isolates that were 
resistant to more than 3 of 8 representative antimicrobial 
drug  classes:  macrolides  (erythromycin),  lincosamides 
(clindamycin), quinolones (levofloxacin or moxifloxacin), 
tetracyclines, sulfa drugs (trimethoprim/sulfamethoxazole), 
aminoglycosides  (gentamicin),  glycopeptides  (vancomy-
cin), and rifampin.
Molecular Typing and PCR to Assess SCCmec Type 
and Presence of the PVL Gene
PFGE  was  performed  as  previously  described  (28). 
Each gel accommodated bacteriophage Lambda ladders (at 
3 places on the gel), DNA from 17 isolates, type strains for 
USA300 and USA400 from the Centers for Disease Control 
and Prevention (Atlanta, GA, USA), and S. aureus NCTC-
8325 (at 3 places on the gel). The gel images were saved 
as TIFF files and BioNumerics computer software (Bio-
systematica, Llandysul, Wales, UK) was used to perform 
cluster analysis. Isolates were classified as the same strain 
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if cluster analysis indicated that they were >80% similar. 
PFGE patterns for clinical isolates were compared visu-
ally and by computer-assisted gel analysis with the type 
strains for USA300 and USA400. We defined CA-MRSA 
as MRSA isolates in either the USA300 or the USA400 
pulsetypes. Multiplex PCR was performed, as previously 
described, to type the SCCmec A (29) and to detect the 
PVL genes (30).
Epidemiologic Data Collection
Epidemiologic data on the isolates were obtained from 
UHL. These data were age, sex, race/ethnicity, inpatient 
status,  intensive  care  unit  status,  long-term-care  facility 
status, hospital admission date, specimen type, specimen 
collection date, the hospital code number, and the Iowa 
Reporting Region. Isolates were considered to have been 
acquired nosocomially if the specimen culture date minus 
the admission date was >2 days.
Statistical Methods
PFGE  patterns  and  antimicrobial  drug  susceptibil-
ity test results were merged with the demographic data. 
These data were analyzed with SAS version 9.1 (SAS In-
stitute, Cary, NC, USA) to assess trends in the frequency 
of USA300/400 in Iowa and to identify possible risk fac-
tors for invasive infections with these strains. We used χ2 
and adjusted χ2 tests to analyze categorical data and linear 
regression and logistic regression to analyze continuous 
data. Alpha was set at 0.05 and all reported p values were 
2-tailed.
Seasonality of infections was analyzed by χ2 analysis. 
Winter was defined as December 22 to March 19, spring as 
March 20 to June 20, summer as June 21 to September 22, 
and fall as September 23 to December 21.
The relationships between CA-MRSA and potential 
risk factors were assessed by univariate analysis. Subse-
quently, stepwise logistic regression was used to identify 
factors independently associated with invasive CA-MRSA 
infection. 
Results
Patients  infected  by  USA300/400  MRSA  were 
younger than those infected by other strains (p<0.0001 
for both time periods; Tables 1, 2). During 2006, more 
males than females were infected with USA300/400 (p 
= 0.06). Most isolates during both time periods were ob-
tained from blood cultures and the distribution of strains 
did not vary by body site. Most patients were hospitalized 
for their infections and the proportion of patients admit-
ted to intensive care units did not vary by strain (p = 0.27 
and p = 0.35). However, the proportion of MRSA infec-
tions that met the definition of nosocomial decreased sig-
nificantly from 26.1% from 1999–2005 to 16.6% in 2006 
(p = 0.0003). During 2006, patients infected with other 
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Table 1. Descriptive epidemiology of invasive MRSA in Iowa, USA, 1999–2005* 
USA type
Characteristic† Total no. (%), N = 1,323  No. (%) USA300/400, n = 26 No. (%) other,‡ n = 1,297 p value 
Mean age, y 67.8 (SD = 17.6) 46.0 (SD = 22.0) 68.2 (SD = 17.2) <0.0001
Female gender 550 (41.6) 9 (34.6) 541 (42.7) 0.549
Inpatient stay 1,124 (85.0) 24 (92.3) 1,100 (84.8) 1.000
ICU admission 221 (16.7) 4 (15.4) 217 (16.7) 0.764
Nosocomial infection 346 (26.2) 5 (19.2) 341 (26.3) 0.306
Specimen type  <0.0001
  Blood  1,256 (94.9)  25 (96.2)  1,231 (94.9) 
  CSF  9 (0.7)  0 9 (0.7) 
  Joint fluid  33 (2.5)  1 (3.9)  32 (2.5) 
  Pleural fluid  8 (0.6)  0 8 (0.6) 
  Other  6 (0.5)  0 (0.0)  6 (0.5) 
Iowa region 0.054
  1  32 (2.4)  1 (3.9)  31 (2.4) 
  2  370 (28.0)  10 (38.5)  360 (27.8) 
  3  335 (25.3)  2 (7.7)  333 (25.7) 
  4  272 (20.6)  4 (15.4)  268 (20.7) 
  5  140 (10.6)  5 (19.2)  135 (10.4) 
  6  63 (4.8)  4 (15.4)  59 (4.5) 
PVL ND ND ND ND
SCCmec IV ND ND ND ND
*MRSA, methicillin-resistant Staphylococcus aureus; ICU, intensive care unit; CSF, cerebrospinal fluid; PVL, Panton-Valentine leukocidin; SCCmec IV, 
staphylococcal chromosomal cassette mec type IV; ND, not done for all isolates.   
†The number of patients missing data on specific variables: age = 13; gender = 11; inpatient = 85; ICU = 356; nosocomial = 358; specimen type = 11; 
Iowa Department of Public Health Reporting Region = 11. 
‡Of the subset of isolates that were typed (N = 180), 173 (96%) were USA100. The remainder clustered with USA200 (3), USA500 (2), or did not match 
an existing USA type.  CA-MRSA, Iowa, USA
MRSA strains were more likely than those infected with 
USA300/400 to have infections that met the definition of 
nosocomial (p = 0.0006).
The  antimicrobial  susceptibility  of  54  invasive 
USA300/400 isolates is shown in Table 3. None of the 
USA300 or USA400 isolates had a multidrug-resistant phe-
notype (e.g., all were resistant to <3 non–β-lactam class-
es). Specifically, none of the USA300 isolates from Iowa 
demonstrated  the  multidrug-resistance  pattern  described 
by Diep et al. that is mediated by the multidrug-resistance 
plasmid pUSA03 (31). All isolates were typeable when the 
DNA was digested with SmaI. We did not identify any in-
vasive MRSA infections caused by USA300/400 between 
1999 and 2002. USA300 caused 3 (1.5%) of 195 infections 
in 2003, 14 (5.8%) of 243 infections in 2004, 7 (2.5%) of 
275 infections in 2005, and 51 (14.9%) of 343 infections in 
2006. USA400 caused 2 (0.7%) of 275 infections in 2005 
and 3 (0.9%) of 343 infections in 2006. The proportion of 
MRSA  isolates  from  invasive  infections  that  were  CA- 
MRSA (either USA300 or USA400) increased significantly 
from 1999–2005 to 2006 (p<0.0001; Figure 1).
Reporting region 4, which had the third largest popula-
tion of the 10 regions, submitted the most isolates; region 
1, which had the fourth smallest population, submitted the 
fewest isolates. We did not find significant differences be-
tween the type of MRSA causing infections and the report-
ing region during 2006. Incidence of infections caused by 
CA-MRSA varied by season during 2006 (p = 0.0004); a 
total of 47.3% of these infections occurred during the sum-
mer (Figure 2).
The full model for predicting invasive infection with 
CA-MRSA  compared  with  HA-MRSA  included  age 
(young vs. old), seasonality, hospital exposure, and speci-
men type. However, the only significant predictors of CA-
MRSA infection compared with HA-MRSA were age <69 
years, which was associated with increased risk (odds ratio 
[OR] 5.1, 95% confidence interval [CI] 2.06–12.64), and 
hospital exposure (OR 0.07, 95% CI 0.01–0.51), which was 
associated with decreased risk.
Discussion
The current study was unique because it evaluated in-
vasive MRSA isolates from a statewide surveillance sys-
tem in a rural area. Most prior studies of the epidemiology 
of CA-MRSA have focused on SSTI among patients in ur-
ban areas.
The published literature documents that incidence of 
CA-MRSA has increased over time in large urban areas. 
For example, Kaplan et al. found that incidence of CA-
MRSA at Texas Children’s Hospital increased each year 
from August 1, 2001 to July 31, 2004 (32). The percent-
age caused by USA300 increased from ≈50% in 2000 to 
>90% in 2003. Of these infections, 95.6% were SSTI and 
4.4% were invasive. EMERGEncy ID NET reported that 
USA300 caused 97% of the MRSA SSTIs seen in emergen-
cy rooms in 11 US metropolitan areas during August, 2004 
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Table 2. Descriptive epidemiology of invasive MRSA in Iowa, USA, 2006* 
USA type
Characteristic† Total no. (%), N = 343  No. (%) USA300/400, n = 54 No. (%) other,‡ n = 289 p value 
Mean age, y 66.3 (SD = 17.0) 50.6 (SD = 21.2) 69.2 (SD = 14.4) <0.0001
Female gender 135 (39.4) 14 (25.9) 121 (41.9) 0.059
Inpatient stay 278 (81.0) 50 (92.6) 228 (78.9) 0.271
ICU admission 56 (16.3) 8 (14.8) 48 (16.7) 0.348
Nosocomial infection 57 (16.6)  1 (1.9)  56 (19.4)  0.0006
Specimen type 0.0021
  Blood  322 (93.9)  45 (83.3)  276 (95.0) 
  CSF  0 0 0
  Joint fluid  13 (3.8)  5 (9.3)  8 (2.9) 
  Pleural fluid  2 (0.6)  2 (3.7)  0
  Other  6 (1.7)  2 (3.7)  5 (1.4) 
Iowa region  0.268
  1  10 (2.9)  0 10 (3.5) 
  2  93 (27.0)  13 (24.1)  80 (27.7) 
  3  49 (14.2)  12 (22.2)  37 (12.8) 
  4  105 (30. 5)  16 (29.6)  88 (30.5) 
  6  20 (5.8)  5 (9.3)  15 (5.2) 
PVL 54 (15.7)  52 (96.3)  2 (0.7)§  <0.0001
SCCmec IV 68 (19.8)  54 (100.0)  13 (4.5)  <0.0001
*MRSA, methicillin-resistant Staphylococcus aureus; ICU, intensive care unit; CSF, cerebrospinal fluid; PVL, Panton-Valentine leukocidin; SCCmec IV, 
staphylococcal chromosomal cassette mec type IV.  
†The number of patients missing data on specific variables: age = 10; Gender = 12; inpatient = 31; ICU = 122; nosocomial = 101; specimen type = 0; 
Iowa Department of Public Health Reporting Region = 6; PVL = 3; SCCmec IV = 3. 
‡Of the subset of isolates that were typed (N = 272) 94% were USA100. The remainder clustered with USA200 (5), USA500 (5), USA600 (1), USA800 
(4), or did not match an existing USA type. 
§Both isolates clustered with USA100 and were SCCmec II. RESEARCH
(15). Seybold et al. demonstrated that by 2004 USA300 had 
become a common cause of MRSA healthcare-associated 
bloodstream infections (28%) and of nosocomial MRSA 
bloodstream infections (20%) at Grady Memorial Hospital 
in Atlanta (21). In contrast, the number of CA-MRSA (pri-
marily USA300) isolates causing invasive infections did 
not increase substantially in Iowa until 2006.
Klevens  et  al.  published  a  study  of  8,987  invasive 
MRSA infections reported from the 9 sites in the Active 
Bacterial  Core  surveillance  (ABCs/Emerging  Infections 
Program Network) from July 2004 through December 2005 
(22). The investigators conducted PFGE on 864 (11.3%) of 
the 7,648 isolates submitted from 8 sites. Of these isolates, 
29%  were  USA300  (16%  of  the  healthcare-associated, 
hospital-onset infections, 22% of the healthcare-associat-
ed, community-onset infections, and 67% of the commu-
nity-associated, community-onset infections); <0.1% were 
USA400. In our study, 4.5% of all isolates we typed and 
14.9% of isolates from 2006 were USA300, which sug-
gested that the incidence of invasive infections caused by 
USA300 remains lower in Iowa than in the urban centers 
studied by Klevens et al.
Unlike the findings of Seybold et al. (21) and Klevens et 
al (22) from studies conducted in urban areas, USA300/400 
rarely caused invasive nosocomial infections in Iowa, a ru-
ral state, during the study period. However, unpublished 
data from the University of Iowa Hospitals and Clinics in-
dicate that these strains are becoming more common causes 
of invasive nosocomial infections, suggesting that the epi-
demiology of MRSA may be changing more slowly in rural 
areas than in large urban areas.
Diep et al. published a follow-up study of previous 
observations by Han et al. (23) about multidrug-resistant 
USA300  isolates  (31).  These  investigators  found  multi-
drug-resistant isolates in Boston and in San Francisco and 
they identified male to male sex, past MRSA infection, 
and use of clindamycin to be risk factors for multiresistant 
USA300. A multidrug resistance plasmid (pUSA03) medi-
ated these drug resistances. Fortunately, we did not identify 
this resistance phenotype among our USA300 isolates from 
Iowa. However, given the rapidity with which plasmid-me-
diated antimicrobial drug resistance can spread, and given 
the epidemic nature of USA300, we will continue surveil-
lance for this and other antimicrobial resistances among 
USA300 isolates in Iowa.
Investigators in the Netherlands, Denmark, and Can-
ada have found nontypeable MRSA among swine (33–37) 
and persons caring for swine (33–36). Strain ST398, which 
is not typeable by PFGE after DNA is digested with SmaI, 
has been found in all of these countries. Iowa produces 
≈25% of the swine in the United States. However, we did 
not identify this strain among the invasive MRSA isolates 
submitted to the UHL.
Our data did not include information about preceding 
influenza infections, but we noted that CA-MRSA was iso-
lated twice from the pleural space; other strains of MRSA 
were not isolated from this site. This finding suggests that 
CA-MRSA may have caused serious pulmonary infections 
in a few persons in Iowa. CA-MRSA, particularly USA300, 
has caused severe infections after influenza (or influenza-
like) infections (20,24). During the influenza pandemic of 
1918, Chickering and Park noted that many patients ac-
quired severe secondary S. aureus pneumonias following 
influenza infections (38). Their observations suggest that 
coincident outbreaks of pandemic influenza and USA300 
pneumonia could be catastrophic.
CA-MRSA, particularly USA300, is a public health 
concern  for  several  other  reasons.  As  noted  previously, 
USA300 is rapidly replacing other strains of MRSA in the 
community (15,31) and has become an important nosocomi-
al pathogen (21). Moreover, the types of infections caused 
by USA300 and the epidemiology of this strain are chang-
ing rapidly (39). Currently, most USA300 and USA400 
isolates  have  fewer  co-resistances  than  do  HA-MRSA 
isolates (13). However, selective pressures can cause ge-
netic drift in favor of more resistances;  papers by Han et 
al. (23) and Diep et al. (31) documented that USA300 can 
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Table 3. Antimicrobial drug susceptibility of 54 invasive MRSA 
USA300/400 isolates, Iowa, USA, 2006*   
Antimicrobial agent  % Susceptible 
Erythromycin  9 
Levofloxacin 57
Clindamycin†  93
Tetracycline  93
Mupirocin 98
Rifampin 98
Trimethoprim/sulfamethoxazole  100
Vancomycin  100
Gentamicin 100
Daptomycin  100
Linezolid 100
*MRSA, methicillin-resistant Staphylococcus aureus.
†Includes D-testing of all erythromycin-resistant, clindamycin-susceptible 
isolates. 
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Figure 1. Number of invasive methicillin-resistant Staphylococcus 
aureus (MRSA) isolates submitted in Iowa, USA, 1999–2006. CA-
MRSA, community-associated MRSA.CA-MRSA, Iowa, USA
acquire additional drug resistance determinants. If USA300 
and USA400 become resistant to oral antimicrobial agents 
and the proportion of invasive MRSA infections caused by 
CA-MRSA continues to increase, many more patients will 
need parenteral vancomycin therapy, which will increase 
the difficulty and cost of treating these infections. Further-
more, as the incidence of CA-MRSA infections increases, 
horizontal transmission of these strains could increase in 
hospitals, making control of MRSA in healthcare settings 
even more difficult (6,40). Nosocomial bloodstream infec-
tions, ventilator-associated pneumonia, and surgical site in-
fections caused by these strains could be devastating given 
the necrotizing nature of the infections.
Our study had several limitations. First, the surveil-
lance system was passive. Consequently, demographic data 
and data about race/ethnicity and exposure to long-term-
care facilities were incomplete and data about prior anti-
microbial drug exposure and underlying diseases were not 
available. Additionally, we could identify the region where 
the specimen originated but not the specific city or county. 
Moreover, a validation study in Iowa found that hospital 
laboratories submit only 37% of the invasive MRSA isolates 
that they identify (D. Dufficy, pers. comm.). However, un-
derreporting affected all regions equally. Furthermore, we 
used different selection criteria for typing invasive MRSA 
isolates submitted from 1999–2005 than we did for those 
submitted in 2006. We typed isolates from 1999–2005 only 
if they had <3 non–β-lactam coresistances, but we typed all 
invasive MRSA isolates from 2006. Thus, we may have in-
troduced selection bias that would predispose the incidence 
of USA300/400 during 1999–2005 toward the null hypoth-
esis (i.e., annual proportion of MRSA isolates that were 
USA300/400 did not change during1999 to 2005) but away 
from the null hypothesis for the incidence of USA300/400 
isolates during 1999–2006 (i.e., H0: The annual proportion 
of MRSA isolates that were USA300/400 was the same 
in 1999–2005 and in 2006). However, given that all the 
USA300/400 isolates identified during 2006 would have 
been  detected  using  the  1999–2005  coresistance  selec-
tion criterion, we believe that we typed all of the invasive 
USA300/400 isolates obtained during 1999–2005.
Some might argue that the incidence of invasive in-
fections  caused  by  CA-MRSA  increased  artificially  be-
cause physicians were more aware of these organisms in 
2006 than they were previously. CA-MRSA certainly has 
become a hot topic. CA-MRSA was initially identified in 
the mid 1990s, and many articles about these organisms 
have been published since then. However, the incidence 
of invasive infections caused by CA-MRSA in Iowa did 
not begin rising until 2006. Moreover, Iowa requires labo-
ratories to send all invasive MRSA isolates to the UHL, 
and laboratory personnel are unlikely to know the details of 
each patient’s infection. Thus, laboratories probably would 
not submit isolates of 1 strain preferentially. Finally, many 
hospitals submitted isolates to the UHL, which suggests 
that submission bias was unlikely in 2006.
In conclusion, the number of invasive MRSA infec-
tions reported in Iowa and the number of invasive infections 
caused by CA-MRSA increased in Iowa from 1999–2005 
to 2006. The increase of CA-MRSA (particularly USA300) 
poses a unique public health threat. Our study demonstrat-
ed that CA-MRSA no longer causes only SSTIs but now 
causes an increased proportion of invasive infections in a 
rural state. This finding is particularly disconcerting in light 
of the severity of these infections and the reports of ne-
crotizing pneumonia caused by USA300 after influenza or 
influenza-like illness. Surveillance systems must continue 
to monitor the number and incidence of infections caused 
by USA300 and to monitor these isolates for changes in 
antimicrobial susceptibility. The relationship between sea-
sons and CA-MRSA warrants further study.
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